tedatioxetine
Sign in to saveTedatioxetine (developmental code name Lu AA24530) is an experimental antidepressant developed by H. Lundbeck A/S for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD). It acts as a triple reuptake inhibitor (TRI) with preference for serotonin and norepinephrine over dopamine, and as an antagonist at 5-HT2A, 5-HT2C, 5-HT3, and α1A-adrenergic receptors. In 2007 Lundbeck and Takeda entered into a partnership that included tedatioxetine but was focused on another, more advanced Lundbeck drug candidate, vortioxetine.
~6 min read
Encyclopedic overview
8 sectionsContents
- Pharmacology
- Pharmacokinetics
- Pharmacodynamics
- Clinical development
- Synthesis
- See also
- References
- External links
{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 454958463 | IUPAC_name = 4-{2-[(4-methylphenyl)sulfanyl]phenyl}piperidine | image = Tedatioxetine.svg | image_class = skin-invert-image | width = 175 | image2 = Tedatioxetine ball-and-stick model.png | image_class2 = bg-transparent | width2 = 250
| tradename = | pregnancy_category = | legal_status = Investigational | routes_of_administration =
Excerpted from Wikipedia’s “tedatioxetine” article, available under the CC BY-SA 4.0 licence.